Patents by Inventor Ene Ette

Ene Ette has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Dose forms
    Patent number: 8431615
    Abstract: The present invention relates to antiviral therapies and compositions for treating or preventing Hepatitis C infections in patients and relates to other methods disclosed herein. The invention also relates to kits and pharmaceutical packs comprising compositions and dosage forms. The invention also relates to processes for preparing these compositions, dosages, kits, and packs.
    Type: Grant
    Filed: October 31, 2005
    Date of Patent: April 30, 2013
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Hui-May Chu, Ene Ette, Lindsay McNair, John Alam
  • Compositions comprising IMPDH inhibitors and uses thereof for treating HCV infection
    Patent number: 7371372
    Abstract: The present invention relates to optimal compositions useful in treating HCV infections in humans. These compositions comprise alpha-interferon or pegylated alpha-interferon and an IMPDH inhibitor selected from VX-148 or VX-944, wherein the IMPDH inhibitor is present in an amount such that a ratio of Cavg/Cmin is between 1 to 10, wherein: Cavg is average plasma concentration produced by said IMPDH inhibitor in said human; and Cmin is estimated trough concentration produced by said IMPDH inhibitor in said human. The present invention also relates to methods of producing and using the optimal compositions to treat HCV infections in humans.
    Type: Grant
    Filed: September 28, 2004
    Date of Patent: May 13, 2008
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Pravin Chaturvedi, Ene Ette
  • Dose forms
    Publication number: 20060105978
    Abstract: The present invention relates to antiviral therapies and compositions for treating or preventing Hepatitis C infections in patients and relates to other methods disclosed herein. The invention also relates to kits and pharmaceutical packs comprising compositions and dosage forms. The invention also relates to processes for preparing these compositions, dosages, kits, and packs.
    Type: Application
    Filed: October 31, 2005
    Publication date: May 18, 2006
    Inventors: Hui-May Chu, Ene Ette, Lindsay McNair, John Alam
  • Combination therapy for HCV infection
    Publication number: 20050112093
    Abstract: The present invention relates to therapeutic combinations comprising VX-497, ribavirin, and interferon. The present invention also relates to methods using the therapeutic combinations of the present invention for treating HCV infection or alleviating one or more symptoms thereof in a patient. The present invention also provides kits comprising the combinations of the present invention.
    Type: Application
    Filed: October 12, 2004
    Publication date: May 26, 2005
    Inventors: Ene Ette, John Alam, Robert Kauffman
  • Optimal compositions and methods thereof for treating HCV infections
    Publication number: 20050074429
    Abstract: The present invention relates to optimal compositions useful in treating HCV infections in humans. These compositions comprise alpha-interferon or pegylated alpha-interferon and an IMPDH inhibitor selected from VX-148 or VX-944, wherein the IMPDH inhibitor is present in an amount such that a ratio of Cavg/Cmin is between 1 to 10, wherein: Cavg is average plasma concentration produced by said IMPDH inhibitor in said human; and Cmin is estimated trough concentration produced by said IMPDH inhibitor in said human. The present invention also relates to methods of producing and using the optimal compositions to treat HCV infections in humans.
    Type: Application
    Filed: September 28, 2004
    Publication date: April 7, 2005
    Inventors: Pravin Chaturvedi, Ene Ette
  • Methods for determining optimal doses for a first investigational administration in humans
    Publication number: 20050015225
    Abstract: The present invention provides a method for determining an optimal dose range of a compound for a first investigational administration of that compound in a human. The method involves stochastic simulation of allometric parameters to produce outcome distributions that provide a basis for selecting an optimal dose range. The present invention also provides optimal doses of compounds under clinical evaluation in the first administration of such compounds to humans.
    Type: Application
    Filed: May 6, 2004
    Publication date: January 20, 2005
    Inventors: Christopher Godfrey, Amit Roy, Ene Ette
  • Optimal compositions and methods thereof for treating HCV infections
    Patent number: 6824769
    Abstract: The present invention relates to optimal compositions useful in treating HCV infections in humans. These compositions comprise alpha-interferon or a derivative thereof and an IMPDH inhibitor, wherein the IMPDH inhibitor is present in an amount such that a ratio of Cavg/Cmin is between 1 to 10, wherein: Cavg is average plasma concentration produced by said IMPDH inhibitor in said human; and Cmin is estimated trough concentration produced by said IMPDH inhibitor in said human. The present invention also relates to methods of producing and using the optimal compositions to treat HCV infections in humans.
    Type: Grant
    Filed: August 28, 2001
    Date of Patent: November 30, 2004
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Pravin Chaturvedi, Ene Ette
  • Optimal compositions and methods thereof for treating HCV infections
    Publication number: 20030068302
    Abstract: The present invention relates to optimal compositions useful in treating HCV infections in humans.
    Type: Application
    Filed: August 28, 2001
    Publication date: April 10, 2003
    Inventors: Pravin Chaturvedi, Ene Ette